Virtus ETF Advisers LLC Provention Bio, Inc. Transaction History

Virtus ETF Advisers LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $3,765 - $13,606	562 Added 1.81%	31,657 $762,000
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $140,549 - $328,674	31,095 New	31,095 $328,000
Q2 2022 Aug 12, 2022	SELL	$3.65 - $7.3 $96,604 - $193,209	-26,467 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.4 - $7.88 $5,314 - $12,316	-1,563 Reduced 5.58%	26,467 $194,000
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $24,389 - $32,242	4,363 Added 18.43%	28,030 $158,000
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $7,029 - $10,345	-1,242 Reduced 4.99%	23,667 $151,000
Q2 2021 Aug 10, 2021	BUY	$6.71 - $11.04 $58,719 - $96,611	8,751 Added 54.16%	24,909 $210,000
Q1 2021 May 17, 2021	BUY	$10.12 - $19.45 $2,833 - $5,446	280 Added 1.76%	16,158 $170,000
Q4 2020 Feb 12, 2021	SELL	$11.79 - $18.94 $66,106 - $106,196	-5,607 Reduced 26.1%	15,878 $269,000
Q3 2020 Nov 13, 2020	SELL	$10.34 - $15.2 $30,151 - $44,323	-2,916 Reduced 11.95%	21,485 $276,000
Q2 2020 Aug 05, 2020	SELL	$7.81 - $17.0 $48,859 - $106,352	-6,256 Reduced 20.41%	24,401 $344,000
Q1 2020 May 14, 2020	SELL	$5.42 - $17.75 $24,178 - $79,182	-4,461 Reduced 12.7%	30,657 $282,000
Q4 2019 Feb 13, 2020	BUY	$5.84 - $14.9 $205,089 - $523,258	35,118 New	35,118 $523,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.